Brief: Diamyd Medical Accelerates Primary Efficacy Readout By 9 Months

Diamyd Medical AB

29/12/2025 07:35

Dec 29 (Reuters) - Diamyd Medical AB DMYDb.ST:

DIAMYD MEDICAL ACCELERATES PRIMARY EFFICACY READOUT BY 9 MONTHS IN TYPE 1 DIABETES PHASE 3 TRIAL FOLLOWING FDA ALIGNMENT AND GUIDANCE

INTERIM EFFICACY READOUT ON TRACK FOR MARCH 2026

Source text: ID:nWkr9tKt4k

Further company coverage: [DMYDb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))